PLX-51107

N/A

Report date: 2024/04/26 20:00:28
NME

Base Information

Drug NamePLX-51107
Drug Alias NamePLX-51107
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBromodomain-containing protein 4 inhibitorsMyc proto-oncogene protein inhibitors
TargetsMyc proto-oncogene proteinBromodomain-containing protein 4
Therapy Area/IndicationsSolid tumoursGraft vs Host DiseaseMyeloproliferative Disorders +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesPlexxikon Inc
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesPlexxikon Inc
Active IndicationsMyeloproliferative DisordersMyelodysplastic SyndromesMyelodysplastic-Myeloproliferative Diseases +[4] 
Inactive IndicationsSolid tumoursGraft vs Host DiseaseLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A
Related LinksN/A